CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 194 filers reported holding CYMABAY THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.14 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $894,600 | -78.6% | 60,000 | -87.5% | 0.00% | -77.8% |
Q1 2023 | $4,187,100 | -4.3% | 480,172 | -31.2% | 0.02% | -60.0% |
Q4 2022 | $4,373,325 | -5.7% | 697,500 | -47.4% | 0.04% | +9.8% |
Q3 2022 | $4,638,000 | +4.8% | 1,325,000 | -11.7% | 0.04% | +24.2% |
Q2 2022 | $4,425,000 | +81.3% | 1,499,900 | +91.1% | 0.03% | 0.0% |
Q1 2022 | $2,441,000 | +11.1% | 785,000 | +20.8% | 0.03% | +50.0% |
Q4 2021 | $2,197,000 | +58.4% | 650,000 | +71.0% | 0.02% | +15.8% |
Q3 2021 | $1,387,000 | +6.0% | 380,052 | +26.7% | 0.02% | +18.8% |
Q2 2021 | $1,308,000 | +40.5% | 300,000 | +46.3% | 0.02% | +45.5% |
Q1 2021 | $931,000 | -12.5% | 205,000 | +10.5% | 0.01% | +83.3% |
Q4 2020 | $1,064,000 | -9.0% | 185,518 | -44.6% | 0.01% | -70.0% |
Q2 2020 | $1,169,000 | +267.6% | 335,000 | +55.8% | 0.02% | +150.0% |
Q1 2020 | $318,000 | -50.1% | 215,000 | -33.8% | 0.01% | -42.9% |
Q4 2019 | $637,000 | +537.0% | 325,000 | +2221.4% | 0.01% | +600.0% |
Q2 2019 | $100,000 | – | 14,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management IV, LLC | 2,023,369 | $27,154,000 | 9.26% |
Omega Fund Management, LLC | 551,477 | $7,401,000 | 5.46% |
Foresite Capital Management III, LLC | 1,562,040 | $20,963,000 | 4.51% |
Versant Venture Management, LLC | 1,048,601 | $14,072,225,000 | 4.39% |
Boxer Capital, LLC | 2,094,000 | $28,101,000 | 3.18% |
Opaleye Management Inc. | 697,500 | $9,360,000 | 2.42% |
Abingworth LLP | 273,417 | $3,667,000 | 2.10% |
DAFNA Capital Management LLC | 294,511 | $3,952,000 | 1.85% |
NEXTHERA CAPITAL LP | 828,655 | $11,121,000 | 1.72% |
Vivo Capital, LLC | 906,000 | $12,158,000 | 1.57% |